
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Manufacturers who use the square root of N plus one rule as part of their overall sampling plan may be surprised to learn of its inadequacies and whether it truly represents the entire batch.
over 23 years ago
May 2003over 23 years ago
Drug Safety in the Limelightover 23 years ago
Outsourcing Outlookover 23 years ago
Particle Attrition by Particle?Surface Friction in Dryers




